Tolfedine 20 mg for dogs 96 tablets
Treatment for alleviation of acute episodes of inflammation and pain in chronic locomotor disease in dogs
Tolfedine Tablets 20mg
2. TOLFEDINE QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Tolfenamic acid 20mg
For a full list of excipients, see section 6.1
3. TOLFEDINE PHARMACEUTICAL FORM
White convex tablets, divisible in two.
4. TOLFEDINE CLINICAL PARTICULARS:
4.2 Indications for use, specifying the target species
Treatment for the alleviation of inflammation and pain and chronic locomotor disease in dogs.
In small dogs : in pathologies of osteoarticular and musculoskeletal systems.
Do not administer to animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product.
4.4 Special warnings for each target species
Long term treatment of over 3 months duration should be under regular veterinary supervision. In particular, dogs with hepatic insufficiency should be closely monitored.
See also 4.5
4.5 Special precautions for use
(i) Special precautions for use in animals
Use in animals less than 6 weeks of age, or in aged animals, may involve additional risk. If such a use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
It is preferable that the product is not administered to animals undergoing general anaesthesia until fully recovered.
Do not exceed the prescribed dosage or duration of treatment.
Animals suffering from a chronic renal insufficiency and requiring an anti-inflammatory treatment may be treated with Tolfenamic acid without requiring an adjustment of the dosage. However, the use of this product is contra-indicated in acute cases of renal insufficiency.
In case of undesirable effects (anorexia, vomiting, diarrhoea, presence of blood in faeces) occurring during the treatment, your veterinarian should be contacted for advice.
(ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental contact with eyes, wash with plenty of water.
Adverse reactions (frequency and seriousness)
Diarrhoea and vomiting may occur in rare cases during the treatment. Moreover, a temporary increase of thirst and/or diuresis may occur. In most of the cases, these signs cease spontaneously after the treatment.
Use during pregnancy, lactation or lay
Although studies in laboratory animals did not show any effect on reproduction, it is not advisable to administer the product during gestation.
Interaction with other medicinal products and other forms of interaction
Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not administer in conjunction with glucocorticosteroids.
Amounts to be administered and administration route
4mg Tolfenamic acid/kg once daily, i.e. 1 tablet for 5kg of bodyweight administered in feed for 3 days according to the following table:
Weight of the animal (kg): Number of tablets
6-8: 1 1/2
10-12.5: 2 1/2
Subject to clinical response, the administration may be repeated every 7 days, ie 3 days of medication followed by 4 days without medication.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, administer symptomatic treatment.
5. TOLFEDINE PHARMACOLOGICAL PROPERTIES
Tolfenamic acid (N-(2-methyl-3-chlorophenyl) anthranilic acid) is a non-steroidal anti-inflammatory drug belonging to the fenamate group. Tolfenamic acid possesses anti-inflammatory, analgesic and antipyretic properties.
The anti-inflammatory activity of Tolfenamic acid is due to inhibition of cyclooxygenase leading to a reduction in prostaglandin and thromboxane synthesis, major inflammatory mediators.
Tolfenamic acid is rapidly absorbed. After a single oral administration of 4mg/kg Tolfenamic acid, the mean maximal plasma concentration (Cmax) of about 4μg/ml is reached in about 1 hour. When the same intake of Tolfenamic acid is taken with food, Cmax is 1.9 ± 1.4μg/ml. These variations are due to a strong enterohepatic recycling of the product.
Distribution, metabolism, excretion
Tolfenamic acid is distributed in all organs with a strong concentration in plasma, digestive tract, liver lungs and kidneys. The concentration in the brain however is low.
Tolfenamic acid and its metabolites do not cross the placenta barrier to any great extent.
Tolfenamic acid is excreted mainly unchanged.
In dogs with renal insufficiency, the elimination of Tolfenamic acid is unchanged.
6. TOLFEDINE PHARMACEUTICAL PARTICULARS
List of excipients
Calcium Hydrogen Phosphate Dihydrate
Shelf life of the veterinary medicinal product as packages for sale 3 years.
Special precautions for storage
Do not store above 25oC
Store in a dry place
Nature and composition of immediate packaging
Box of 1 PVC – aluminium blister of 8 tablets
Box of 2 PVC-aluminium blisters of 8 tablets
Box of 12 PCV-aluminium blisters of 8 tablets
Box of 24 PVC-aluminium blisters of 8 tablets
Box of 48 PVC-aluminium blisters of 8 tablets
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste
materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Vétoquinol UK Limited
Buckingham Industrial Park